[Guoxin Securities] Zhongheng Group: Cooperating with Kangmei in supply chain, channel and medical services to unleash the company's huge potential
[Changjiang Securities] Zhongheng Group: After deducting high growth in performance, product introduction continues
[CIC Securities] Zhongheng Group: Xueshuantong is growing steadily, and the extension strategy continues to advance.
[Changjiang Securities] Zhongheng Group: rapid growth in performance and strong extension expectation
[CIC Securities] Zhongheng Group: performance in line with expectations, implementation of overseas new drug introduction strategy
[southwest Securities] comments on the 2014 annual report of Zhongheng Group: the sales volume of Xuantong for injection is stable, and the net profit is growing high.
[CIC Securities] Zhongheng Group: comments on the results of Drug bidding in Hunan Province
[CIC Securities] Zhongheng Group: Xueshuantong growth is in line with expectations, reducing holdings of Guohai to increase net profit
[CIC Securities] Zhongheng Group: high performance growth is guaranteed, waiting for valuation repair
[Changjiang Securities] Zhongheng Group: strong endogenous growth, Panax notoginseng price reduction and thickening performance
【东北证券】中恒集团:前三季主业大增43.24%,Q3明显加快
【国信证券】中恒集团2014年3季报报点评:内生强劲,期待外延,大股东参与定增显信心
【华泰证券】中恒集团:血栓通延续较高增速,外延步伐加快
【方正证券】中恒集团:业绩符合预期,三七价格下降将持续提升盈利能力
【西南证券】中恒集团2014年三季报点评:前三季度净利润快速增长,超市场预期
【中投证券】中恒集团:血栓通高增长持续,扣非净利润增长超预期
【中投证券】中恒集团:浙江药品集中采购实施方案(征求意见稿)点评
【联讯证券】中恒集团半年报点评:医药业务稳定增长,并购扩张有望加速
【华泰证券】中恒集团:控费致增速放缓,期待外延扩张
【国信证券】-中恒集团:内生延续强劲,期待外延加速